News

MyChesCo on MSN2d
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported a return to profitability in the second quarter, driven by the termination of a regional licensing deal and renewed strategic ...
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Arbutus (ABUS) Q2 Revenue Surges 529%
Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arbutus: Q2 Earnings Snapshot
Arbutus Biopharma Corp. ABUS) on Wednesday reported second-quarter net income of $2.5 million, after reporting a loss in the ...